CompletedPhase 2NCT03180294

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

Studying Vaginal carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
NRG Oncology
Principal Investigator
Debra Barton
NRG Oncology
Intervention
Bupropion 150 mg XL(drug)
Enrollment
230 enrolled
Eligibility
18 years · FEMALE
Timeline
20172021

Study locations (30)

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03180294 on ClinicalTrials.gov

Other trials for Vaginal carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Vaginal carcinoma

← Back to all trials